AbbVie Wins EU Approval for RINVOQ in Pediatric JIA
North Chicago, Illinois, U.S., September 22, 2026 AbbVie has announced that the European Commission has approved RINVOQ® (upadacitinib) for...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
North Chicago, Illinois, U.S., September 22, 2026 AbbVie has announced that the European Commission has approved RINVOQ® (upadacitinib) for...
